Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

News Flash! The FDA Grants Priority Review to a Co-Formulation of Viread (Tenofovir) and Emtriva (Emtricitabine)

July 27, 2004

Gilead Sciences the maker of Viread and Emtriva announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to a new fixed dose co-formulation of the company's anti-HIV medications Viread and Emtriva.

Under this status, the New Drug Application (NDA) will review the new co-formulation and make a decision by September 12th, 2004. The proposed co-formulation will contain 300 mg of tenofovir (Viread) and 200 mg of emtricitabine (Emtriva). This new medication if it gets approved, will have to be taken in combination with at least one other antiretroviral.

For more information on this news go to: www.Gilead.com.





  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
 

Tools
 

Advertisement